Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
Ado-Trastuzumab Emtansine
/ adverse effects
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents, Immunological
/ adverse effects
Breast Neoplasms
/ chemistry
Confidence Intervals
Disease Progression
Female
Humans
Middle Aged
Progression-Free Survival
Receptor, ErbB-2
Retrospective Studies
Treatment Outcome
Ado-Trastuzumab
Breast Cancer
HER2
Pertuzumab
T-DM1
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
27 Oct 2021
27 Oct 2021
Historique:
received:
23
03
2021
accepted:
13
10
2021
entrez:
28
10
2021
pubmed:
29
10
2021
medline:
8
2
2022
Statut:
epublish
Résumé
Docetaxel in combination with two HER2-directed therapies, trastuzumab and pertuzumab, is the current standard frontline therapy for patients with metastatic HER2-positive breast cancer. Ado-trastuzumab (T-DM1), an antibody-drug conjugate of trastuzumab and a cytotoxic microtubule-inhibitory agent, emtansine, is approved in patients that have progressed with prior trastuzumab-based therapy. However, the benefit of T-DM1 in patients previously treated with pertuzumab therapy for metastatic breast cancer remains unclear. We identified thirty-three adults with metastatic HER2-positive breast cancer treated between March 2013 and July 2018 with T-DM1 either as subsequent therapy after progression on a pertuzumab-based regimen (i.e., "pertuzumab-pretreated") or without prior exposure to pertuzumab (i.e., "pertuzumab-naïve"). Collected data included patient demographics, treatment history, adverse events, and clinical outcomes. For both cohorts receiving T-DM1, the primary endpoint was PFS and secondary endpoints were overall survival (OS), overall response rate (ORR), clinical benefit rate (CBR), and T-DM1-related toxicity rate. Pertuzumab-pretreated patients (n = 23, with 21 evaluable for T-DM1 efficacy) had a median PFS of 9.5 months (95% CI: 2.9-NA), 1-year OS rate of 67.4% (95% CI: 50.0-90.9%) with an unreached median, ORR of 14.3% (95% CI: 3.0-36.3%), and CBR of 52.4% (95% CI: 29.8-74.3%), with none of these measures being statistically different than those estimated for the pertuzumab-naïve group (n = 10). Treatment with T-DM1 after prior pertuzumab exposure (median T-DM1 duration 2.9 months) resulted in no grade ≥ 3 adverse events. In our cohort, prior exposure to pertuzumab did not significantly impact T-DM1's clinical efficacy or safety profile as second- or later-line therapy in patients with metastatic HER2-positive breast cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Docetaxel in combination with two HER2-directed therapies, trastuzumab and pertuzumab, is the current standard frontline therapy for patients with metastatic HER2-positive breast cancer. Ado-trastuzumab (T-DM1), an antibody-drug conjugate of trastuzumab and a cytotoxic microtubule-inhibitory agent, emtansine, is approved in patients that have progressed with prior trastuzumab-based therapy. However, the benefit of T-DM1 in patients previously treated with pertuzumab therapy for metastatic breast cancer remains unclear.
METHODS
METHODS
We identified thirty-three adults with metastatic HER2-positive breast cancer treated between March 2013 and July 2018 with T-DM1 either as subsequent therapy after progression on a pertuzumab-based regimen (i.e., "pertuzumab-pretreated") or without prior exposure to pertuzumab (i.e., "pertuzumab-naïve"). Collected data included patient demographics, treatment history, adverse events, and clinical outcomes. For both cohorts receiving T-DM1, the primary endpoint was PFS and secondary endpoints were overall survival (OS), overall response rate (ORR), clinical benefit rate (CBR), and T-DM1-related toxicity rate.
RESULTS
RESULTS
Pertuzumab-pretreated patients (n = 23, with 21 evaluable for T-DM1 efficacy) had a median PFS of 9.5 months (95% CI: 2.9-NA), 1-year OS rate of 67.4% (95% CI: 50.0-90.9%) with an unreached median, ORR of 14.3% (95% CI: 3.0-36.3%), and CBR of 52.4% (95% CI: 29.8-74.3%), with none of these measures being statistically different than those estimated for the pertuzumab-naïve group (n = 10). Treatment with T-DM1 after prior pertuzumab exposure (median T-DM1 duration 2.9 months) resulted in no grade ≥ 3 adverse events.
CONCLUSIONS
CONCLUSIONS
In our cohort, prior exposure to pertuzumab did not significantly impact T-DM1's clinical efficacy or safety profile as second- or later-line therapy in patients with metastatic HER2-positive breast cancer.
Identifiants
pubmed: 34706686
doi: 10.1186/s12885-021-08894-2
pii: 10.1186/s12885-021-08894-2
pmc: PMC8549287
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
pertuzumab
K16AIQ8CTM
Ado-Trastuzumab Emtansine
SE2KH7T06F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1150Informations de copyright
© 2021. The Author(s).
Références
Breast Cancer. 2019 Jul;26(4):492-498
pubmed: 30737616
J Clin Oncol. 2016 Oct 10;34(29):3511-3517
pubmed: 27298406
Lancet Oncol. 2016 Mar;17(3):367-377
pubmed: 26874901
Lancet Oncol. 2014 Jun;15(7):689-99
pubmed: 24793816
J Clin Oncol. 2017 Jan 10;35(2):141-148
pubmed: 28056202
J Clin Oncol. 2018 Sep 10;36(26):2736-2740
pubmed: 29939838
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
N Engl J Med. 2012 Jan 12;366(2):109-19
pubmed: 22149875
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
Curr Opin Obstet Gynecol. 2011 Feb;23(1):37-43
pubmed: 21500375
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Lancet Oncol. 2018 Mar;19(3):323-336
pubmed: 29433963
Lancet Oncol. 2020 Apr;21(4):519-530
pubmed: 32171426
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Clin Breast Cancer. 2020 Apr;20(2):e181-e187
pubmed: 31735691
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153